Results 181 to 190 of about 434,626 (386)

Effect of Time Delay and Antibodies on HCV Dynamics with Cure Rate and Two Routes of Infection

, 2018
A. M. Ełaiw, Shafeek A. Ghaleb, Aatef Hobiny   +2 more
openalex   +2 more sources

Reference Intervals for Lymphocyte Subpopulations in Healthy Chinese Han Adults: A Single‐Center Study

Journal of Clinical Laboratory Analysis, EarlyView.
Correlation matrix analysis of lymphocyte parameters. The correlation matrix showed the positive (red) or negative (blue) correlation of two parameters; the color intensity reflected the correlation coefficient. Conducting lymphocyte testing in health management can help monitor immune status, evaluate health risks, analyze pathogenesis of diseases ...
An‐Na Jiang, Lin‐Zi Miao, Yan Gong, Ran You, Yao Lu, Chen‐Xue Qu   +5 more
wiley   +1 more source

Telaprevir for retreatment of HCV infection.

New England Journal of Medicine, 2011
S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G. Foster, A. Horban, P. Ferenci, F. Nevens, B. Müllhaupt, P. Pockros, R. Terg, D. Shouval, B. van Hoek, O. Weiland, R. V. van Heeswijk, S. De Meyer, D. Luo, G. Boogaerts, R. Polo, G. Picchio, M. Beumont   +24 more
semanticscholar   +1 more source

[HCV reinfection after liver transplantation for HCV cirrhosis].

Le infezioni in medicina, 2005
Cirrhosis due to hepatitis C virus (HCV) infection is now the most frequent indication for orthotopic liver transplantation (OLT). Recurrence of hepatitis C infection is the major cause of late mortality in patients undergoing OLT for hepatitis C cirrhosis.
PASQUALE, Giuseppe, IANNICELLI P, MARTINI S, MOGAVERO AR, CAPRIO N.   +4 more
openaire   +2 more sources

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters

The Journal of Clinical Pharmacology, EarlyView.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies ...
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Nancy Agrawal, Janet Hammond   +9 more
wiley   +1 more source

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication” [PDF]

Clinical and Molecular Hepatology
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu   +3 more
doaj   +1 more source

Performance of PNAEQ participant’s results for HIV and HCV infection in the First EQA round 2019 [PDF]

, 2019
The Portuguese National External Quality Assessment Program (PNAEQ) has been collaborating with Labquality since 2002. One of the first schemes distributed to PNAEQ participants was for HIV laboratory tests, followed by HCV laboratory tests scheme in ...
Cardoso, Ana, Correia, Helena, Faria, Ana Paula, Järvenpää, Marsa, Pereira, Edna, Ventura, Catarina, Viegas, Silvia   +6 more
core  

Boceprevir for previously treated chronic HCV genotype 1 infection.

New England Journal of Medicine, 2011
B. Bacon, S. Gordon, E. Lawitz, P. Marcellin, J. Vierling, S. Zeuzem, F. Poordad, Z. Goodman, H. Sings, N. Boparai, M. Burroughs, C. Brass, J. Albrecht, R. Esteban   +13 more
semanticscholar   +1 more source

A continuous ¹³C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT [PDF]

, 2008
Gadi Lalazar, Orit Pappo, Tiberiu Hershcovici, T. Hadjaj, M. Shubi, Hana Ohana, Nilla Hemed, Yaron Ilan   +7 more
openalex   +1 more source

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source